论文部分内容阅读
目的探讨巴曲酶治疗急性脑梗死的临床疗效。方法选择2006年1月至2009年1月我科收治的符合入选标准的脑梗死患者218例,根据治疗方法分为治疗组118例和对照组100例。治疗组采用基础治疗加巴曲酶,对照组采用基础治疗并对比疗效。结果治疗后5、15 d两组神经功能缺损程度评分比较差异有统计学意义(P<0.05),两组总有效率比较差异有统计学意义(P<0.05)。结论巴曲酶注射液治疗急性期脑梗死患者疗效确切,安全可靠,不良反应较少,应用方便。
Objective To investigate the clinical efficacy of batroxobin in the treatment of acute cerebral infarction. Methods A total of 218 patients with cerebral infarction who met the inclusion criteria from January 2006 to January 2009 were divided into treatment group (n = 118) and control group (n = 100). The treatment group was treated with batroxobin, while the control group was treated with basic treatment and the curative effect was compared. Results The score of neurological deficit in both groups had statistical significance at 5 and 15 days after treatment (P <0.05). There was significant difference in the total effective rate between the two groups (P <0.05). Conclusion Batroxobin injection in patients with acute cerebral infarction is effective, safe and reliable, with fewer adverse reactions and convenient application.